Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 11/20 | 0.55 |
| ▸ | ACHE | P22303 | 9/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328956 | 0.81 | HTR4 (0.66) | HTR4ACHE | |
| Hydrochloric Acid SCHEMBL6329100 | 0.80 | HTR4 (0.65) | HTR4ACHE | |
| SCHEMBL6330777 | 0.79 | ACHE (0.67) | HTR4ACHE | |
| SCHEMBL6327293 | 0.79 | FAAH (0.46) | HTR4ACHEFAAH | |
| SCHEMBL7257694 | 0.74 | DRD2 (0.37) | HTR4DRD2DRD4 | |
| SCHEMBL7360030 | 0.71 | HTR4 (0.69) | HTR4ACHE | |
| SCHEMBL7350324 | 0.71 | HTR4 (1.00) | HTR4ACHE | |
| SCHEMBL11400510 | 0.70 | TDP1 (0.52) | HTR4ACHEHDAC3HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL1315280 | 0.70 | HTR4 (0.53) | HTR4ACHEITGB3ITGA2BHDAC3 | |
| SCHEMBL14564866 | 0.70 | HTR4 (0.62) | HTR4ACHEITGB3ITGA2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979690-B2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2003-11-06 | — | — | US | disclosed |
| EP-1325921-A2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | Pfizer Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | HRH4, HRH2, HTR4 | HTR4 3/4885ACHE 3937/4885ITGB3 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.